ArticleArthritis care & research2016
Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
Article in Arthritis care & research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Guideline
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.Arthritis care & research · 2019Guideline
- Trial
- Anti-Cell Staining Patterns in Juvenile Idiopathic Arthritis-Associated Uveitis: A Peek Behind the Curtain.Journal of clinical medicine · 2026Article
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- Juvenile idiopathic arthritis during 20 years in Sweden: Characteristics of children, therapy interventions, occurrence of uveitis and ocular complications.Acta ophthalmologica · 2025Article
- Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.Rheumatology (Oxford, England) · 2025Article
- Article
- Uveitis associated with juvenile arthritis: a continued cohort study 40 years after uveitis onset.Pediatric rheumatology online journal · 2022Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis.Frontiers in pediatrics · 2022Article
- Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review.Drugs - real world outcomes · 2020Review
- A review of ocular adverse events of biological anti-TNF drugs.Journal of ophthalmic inflammation and infection · 2020Review
- Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany.Arthritis research & therapy · 2020Article
- Improving quick and accurate diagnosis of childhood JIA-uveitis from a pediatric rheumatology perspective.Expert review of ophthalmology · 2020Article
- Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.Rheumatology (Oxford, England) · 2019Article
- Visual Function And Quality Of Life In A Cohort Of Swedish Children With Juvenile Idiopathic Arthritis.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Identification of Ocular Autoantigens Associated With Juvenile Idiopathic Arthritis-Associated Uveitis.Frontiers in immunology · 2019Article
- Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort.Arthritis research & therapy · 2018Observational
- [Registry-based research in ophthalmology].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBased on a nationwide database, this study analyzed the influence of methotrexate (MTX), tumor necrosis factor (TNF) inhibitors, and a combination of the 2 medications on uveitis occurrence in juvenile idiopathic arthritis (JIA) patients.
methodsData from the National Paediatric Rheumatological Database in Germany were used in this study. Between 2002 and 2013, data from JIA patients were annually documented at the participating pediatric rheumatologic sites. Patients with a JIA disease duration of <12 months at initial documentation and ≥2 years of followup were included in this study. The impact of antiinflammatory treatment on the occurrence of uveitis was evaluated by discrete-time survival analysis.
resultsA total of 3,512 JIA patients (mean ± SD age 8.3 ± 4.8 years, 65.7% female, 53.2% antinuclear antibody positive, and mean ± SD age at arthritis onset 7.8 ± 4.8 years) fulfilled the inclusion criteria. Mean ± SD total followup time was 3.6 ± 2.4 years. Uveitis developed in a total of 180 patients (5.1%) within 1 year after arthritis onset. Uveitis onset after the first year was observed in another 251 patients (7.1%). Disease-modifying antirheumatic drug (DMARD) treatment in the year before uveitis onset significantly reduced the risk for uveitis as follows: MTX: hazard ratio (HR) 0.63, P = 0.022; TNF inhibitors: HR 0.56, P < 0.001; and a combination of the 2 medications: HR 0.10, P < 0.001. Patients treated with MTX within the first year of JIA had an even a lower uveitis risk (HR 0.29, P < 0.001).
conclusionThe use of DMARDs in JIA patients significantly reduced the risk for uveitis onset. Early MTX use within the first year of disease and the combination of MTX with a TNF inhibitor had the highest protective effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.